Results 31 to 40 of about 105,036 (275)
Development of Biosimilars in Brazil
Fronteiras: Journal of Social, Technological and Environmental Science, 2016 This article presents a brief overview of the biosimilar industry in Brazil and in the world. Biosimilars are drugs originating from therapeutic or biological proteins, whose patents are expired or are going to expire.
Eduardo Braz Pereira Gomes +4 more
doaj +1 more source
SAGE Open, 2021 Do different pharmaceutical product liability regimes in different countries induce propensity to patent? We exploit the variation in pharmaceutical liability and litigation rules across firms in the pharmaceutical industry and countries to explain the ...
Mitja Kovac, Salvini Datta, Rok Spruk
doaj +1 more source
Public and Private International Law Bulletin, 2021 Vaccine nationalism is an obstacle to combating the global COVID-19 pandemic. Since the production of COVID-19 vaccines is still insufficient to meet the needs of the world population, developed countries primarily purchase them for their populations ...
Meltem Sarıbeyoğlu Skalar
doaj +1 more source
The Value of Failures in Pharmaceutical R&D [PDF]
, 2012 We build a cumulative innovation model in which both success and failure provide valuable information for future research. To test this learning mechanism, we use a dataset covering outcomes of world-wide R&D projects in the pharmaceutical industry, and ...
Chiou, Jing-Yuan +3 more
core
Pediatric Blood &Cancer, EarlyView.ABSTRACT Introduction We developed MedSupport, a multilevel medication adherence intervention designed to address root barriers to medication adherence. This study sought to explore the feasibility and acceptability of the MedSupport intervention strategies to support a future full‐scale randomized controlled trial.
Elizabeth G. Bouchard +8 more
wiley +1 more source
Patents and licensing in pharmaceutical industry [PDF]
Makedonsko Farmacevtski Bilten, 2005 Intellectual property rights (IPR) have been defined as ideas, inventions, and creative expressions based on which there is a public willingness to bestow the status of property.
Katerina Ancevska Netkovska +3 more
doaj
Brexit – The Consequences for Pharmaceutical Patents and Supplementary Protection Certificates
British Journal of Pharmacy, 2021 Now that the UK has left the EU, and the transition period following this departure is over, we have a clearer view on the implications of Brexit on intellectual property rights and the consequences for UK based pharmaceutical companies. Although little
Harry Melville O'Brien +2 more
doaj +1 more source
Case Law: A Review of Selected Pharmaceutical Patents in the UK Courts during 2021
British Journal of Pharmacy, 2022 Patents lie at the interface between technology and law. This review provides a summary of four high-profile cases from 2021 in which patents in the pharmaceutical or medical space were litigated in the UK Courts.
Sarah-Jane Crawford +2 more
doaj +1 more source
Awaking the Sleeping Dragon: The Evolving Chinese Patent Laws and its Implications for Pharmeceutical Patents [PDF]
, 2011 Part I of this Comment will discuss the development of the Chinese IP system and discuss why it has been ineffective in protecting pharmaceutical patents by comparing it to the US patent system.
Wu, Rachel T.
core +1 more source
Function‐driven design of a surrogate interleukin‐2 receptor ligand
FEBS Letters, EarlyView.Interleukin (IL)‐2 signaling can be achieved and precisely fine‐tuned through the affinity, distance, and orientation of the heterodimeric receptors with their ligands. We designed a biased IL‐2 surrogate ligand that selectively promotes effector T and natural killer cell activation and differentiation. Interleukin (IL) receptors play a pivotal role in
Ziwei Tang +9 more
wiley +1 more source